In yesterday’s Wall Street session, Nuvation Bio Inc (NYSE:NUVB) shares traded at $2.70, up 4.65% from the previous session.
NUVB stock price is now 7.41% away from the 50-day moving average and -2.93% away from the 200-day moving average. The market capitalization of the company currently stands at $911.43M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $1.40 to $10, Jefferies Upgraded its rating from Hold to Buy for Nuvation Bio Inc (NYSE: NUVB). On March 26, 2024, BTIG Research Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock keeping its target price maintained at $5, while ‘Jefferies’ rates the stock as ‘Hold’
In other news, Wang Junyuan Jerry, CEO, ANHEART THERAPEUTICS LTD. sold 56,361 shares of the company’s stock on Nov 11 ’24. The stock was sold for $162,883 at an average price of $2.89. Upon completion of the transaction, the CEO, ANHEART THERAPEUTICS LTD. now directly owns 3,866,228 shares in the company, valued at $10.44 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 08 ’24, Director Mashal Robert bought 100,000 shares of the business’s stock. A total of $220,000 was incurred on buying the stock at an average price of $2.20. This leaves the insider owning 100,000 shares of the company worth $0.27 million. A total of 32.40% of the company’s stock is owned by insiders.
During the past 12 months, Nuvation Bio Inc has had a low of $1.21 and a high of $4.16. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 9.57, and a quick ratio of 9.57. The fifty day moving average price for NUVB is $2.521 and a two-hundred day moving average price translates $2.77615 for the stock.
The latest earnings results from Nuvation Bio Inc (NYSE: NUVB) was released for 2024-09-30. The net profit margin was -24619.84% and return on equity was -95.54% for NUVB.
